| 11.385 -0.065 (-0.57%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.94 | 1-year : | 16.28 |
| Resists | First : | 11.93 | Second : | 13.94 |
| Pivot price | 10.56  |
|||
| Supports | First : | 9.84 |
Second : | 8.54 |
| MAs | MA(5) : | 11.38 |
MA(20) : | 10.17 |
| MA(100) : | 9.61 |
MA(250) : | 7.98 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 84.1 |
D(3) : | 86.8 |
| RSI | RSI(14): 67.8 |
|||
| 52-week | High : | 11.93 | Low : | 4.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VIR ] has closed below upper band by 24.5%. Bollinger Bands are 84.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.67 - 11.74 | 11.74 - 11.79 |
| Low: | 11.02 - 11.11 | 11.11 - 11.17 |
| Close: | 11.3 - 11.44 | 11.44 - 11.54 |
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Sat, 05 Sep 2026
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Sat, 05 Sep 2026
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Thu, 03 Sep 2026
Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Tue, 01 Sep 2026
Vir Biotechnology stock hits 52-week high at 11.66 USD - Investing.com
Mon, 31 Aug 2026
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Tue, 25 Aug 2026
Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 169 (M) |
| Held by Insiders | 1.2979e+008 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 19,190 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.6796e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -83 % |
| Operating Margin | 30.7 % |
| Return on Assets (ttm) | -14.6 % |
| Return on Equity (ttm) | -26.1 % |
| Qtrly Rev. Growth | 19 % |
| Gross Profit (p.s.) | 366.35 |
| Sales Per Share | 1.90711e+008 |
| EBITDA (p.s.) | -1.13258e+008 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -203 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.6 |
| Dividend | 0 |
| Forward Dividend | 1.904e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|